Novartis announced that investigational, once-daily, inhaled QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate or IND/GLY/MF) was superior to QMF149 (indacaterol acetate and ...
TOKYO and LONDON, Oct. 1, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) notes that Novartis has announced positive results from its Phase III IRIDIUM trial. The results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback